摘要
目的:探讨CIK细胞联合VAD方案对多发性骨髓瘤(multiple myeloma,MM)的预后的影响。方法:按照是否接受CIK细胞治疗将46例MM患者均分为观察组22例和对照组24例。对照组接受单纯VAD方案化疗,观察组在此基础上给予CIK细胞治疗,比较两组预后效果。结果:两组患者总有效率基本相似,差异无统计学意义(P>0.05),但观察组患者CR率明显高于对照组(P<0.05);观察组患者治疗后成骨细胞水平均显著高于对照组,破骨细胞、浆细胞比率、IgA和IgG水平均显著低于对照组(P<0.05);观察组患者白蛋白、血红蛋白升高幅度和血沉、β2-MG下降幅度均显著高于对照组(P<0.05);观察组心电图异常、心肌酶升高、肌酐升高发生率显著高于对照组(P<0.05)。结论:采用CIK细胞联合VAD方案治疗MM能够有效提高临床疗效,改善患者客观指标。
Objective： To explore the effect of CIK cells comined with VAD regimen on prognosis of patients with multiple myeloma（MM）. Methods： Forty-six cases of MM were divided into observation group and control group, the control group was treated by VAD and the observation group was treated by CIK cells comined with VAD. The prognosis between 2 groups was compared. Results ： The total efficiency was not significantly different between the 2 groups （ P 〉 0.05 ） ; the CR in the observation group was significantly higher than that in control group （ P 〈 0.05 ） ; the levels of osteocytes in observation group were higher than those in control group （ P 〈 0.05 ） ; the levels of osteoclasts, plasma cells, IgA and IgG in observation group were lower than those in control group （ P 〈 0.05 ） ; the increasing ranges of albumin and hemoglobin, and the decreasing range of blood sedimentation and β2-MG in observation group were higher than those in control group（ P 〈 0. 05 ） ; the incidences of abnormal electrocardiogram, myocardial enzyme and creatinine in observation group were higher than those in control group （ P 〈 0.05 ）. Conclusion ： CIK cells comined with VAD regimen can enhance the therapeutic effects on the patients with multiple myeloma, improve the objective index and reduce the risk of adverse reactions, thus may be applicable to clinical practice.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2017年第2期490-493,共4页
Journal of Experimental Hematology
关键词
CIK细胞
VAD方案
多发性骨髓瘤
cytokine-induced killer cell
VAD regimen
multiple myeloma
